Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-17
Trial Details
NCT Number NCT07665879
Lead Sponsor Eli Lilly and Company
Conditions Overweight, Obesity
Enrollment 115 participants
Start Date 2026-06-24
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-16